This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Noxxon Pharma Ag. Active years: 2011.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2011
Title: Mathias Bell: Innovator in Nucleic Acid Technology
Introduction
Mathias Bell is a prominent inventor based in Berlin, Germany. He has made significant contributions to the field of biotechnology, particularly in the development of nucleic acid-based antagonists. His innovative work has the potential to impact therapeutic approaches for various medical conditions.
Latest Patents
Mathias Bell holds a patent for "CGRP binding nucleic acids." This invention relates to an antagonist for CGRP and amylin, where the antagonist is a nucleic acid that binds to CGRP or amylin. The nucleic acid preferably comprises an L-nucleotide, showcasing the specificity and potential efficacy of his invention.
Career Highlights
Mathias Bell is associated with Noxxon Pharma AG, a company focused on developing innovative therapies. His work at Noxxon Pharma AG has allowed him to explore and expand the applications of his inventions in the pharmaceutical industry.
Collaborations
Some of his notable coworkers include Florian Jarosch and Sven Klussmann. Their collaboration has likely contributed to the advancement of research and development in their respective fields.
Conclusion
Mathias Bell's contributions to nucleic acid technology exemplify the innovative spirit of modern biotechnology. His work continues to pave the way for new therapeutic solutions.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile